May 6 Financial Quick Takes: Athenex, Spiral

Athenex raises $100M to advance Oraxol
Looking to fund commercialization activities for Oraxol and advance its oncology pipeline and actinic keratosis therapy, Athenex Inc. (NASDAQ:ATNX) raised $100 million in a private placement through the sale of 10 million shares at $10 to Perceptive Advisors, Avoro Capital Advisors and OrbiMed Advisors. Oraxol, an oral formulation of paclitaxel and encequidar (HM30181A), is in Phase III testing for breast and gastric cancer. Athenex was up $2.87 (28%) to $12.99 on Monday...